March 11, 2016
Researchers from the University of Illinois at Chicago have just published a study that demonstrated a difference between Caucasians and non-Caucasians for those with myeloproliferative neoplasms.
In an analyisis of data spanning over a decade, Dr. Rondelli et al found that Caucasian patients with PV and ET had a higher risk of progression to myelofibrosis, but that Caucasian race emerged as an independent prognostic factor protective against cardiovascular thrombosis in PV and ET patients. Non-Caucasian race was also a significant risk factor for hemorrhagic complications of PV and ET and this was largely driven by African American ethnicity. Click here to read more.